



1653

P#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Ping Gao et al. ) ATTORNEY DOCKET NO.: 6239.N  
SERIAL NO.: 10/047,902 ) GROUP ART UNIT: Unknown  
FILED: January 14, 2002 ) EXAMINER: Unknown  
TITLE: CHEMOTHERAPEUTIC MICRO-EMULSION COMPOSITIONS OF  
PACLITAXEL WITH IMPROVED ORAL BIOAVAILABILITY  
DATE: March 6, 2003

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement is being deposited with the United States Postal Service as First Class Mail in a package addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 6, 2003.

*Bernadette Y. Harper*  
Bernadette Y. Harper

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97(b)

Applicants hereby submit copies of patents, publications and/or other information of which they are aware and which may be related to the examination of this application, and in respect of which there may be a duty to disclose under 37 CFR § 1.56 and §§ 1.97 - 1.98 as supplemented by MPEP § 609. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed within three months of the filing date of the above-cited patent application or prior to the mailing of a first Office action on the merits, in accordance with 37 CFR § 1.97(b). Accordingly, Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application. No fee is believed payable; however, if it is determined that a fee is payable, please charge Deposit Account No. 19-1025.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.

Respectfully submitted,



David B. Fournier  
Agent for Applicant  
Registration No. 51,696  
Tel. 847-581-5144

Address correspondence to:  
Pharmacia Corporation  
P.O. Box 1027  
St. Louis, MO 63006

Enclosures:  
Form PTO-1449  
Copies of cited documents  
Post Card

Form PTO-1449  
(Rev. 8-88)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

Serial No.

6239.N

10/047,902

Applicant

Ping Gao et al.

Filing Date


January 14, 2002

Group No.

1614

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



RECEIVED  
MAR 12 2003  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner Initial*	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	4,250,997	Feb 17, 1981	Bodenmann et al.	206	528	
	4,498,421	Feb 12, 1985	Lovitt	119	17	
	5,264,223	Nov 23, 1993	Yamamoto et al.	424	451	
	5,415,869	May 16, 1995	Straubinger et al.	424	450	
	5,424,073	Jun 13, 1995	Rahman et al.	424	450	
	5,439,686	Aug 08, 1995	Desai et al.	424	451	
	5,504,102	Apr 02, 1996	Agharkar et al.	514	449	
	5,641,803	Jun 24, 1997	Carretta et al.	514	449	
	5,648,090	Jul 15, 1997	Rahman et al.	424	450	
	5,665,382	Sep 09, 1997	Grinstaff et al.	424	450	
	5,670,537	Sep 23, 1997	Canetta et al.	514	449	
	5,683,175	Nov 04, 1997	Golz	362	338	
	5,728,687	Mar 17, 1998	Bissery	514	90	
	5,756,123	May 26, 1998	Yamamoto et al.	424	451	
	5,908,835	Jun 01, 1999	Bissery	514	33	
	5,916,596	Jun 29, 1999	Desai et al.	424	489	
	5,968,972	Oct 19, 1999	Border et al.	514	449	
	6,028,054	Feb 22, 2000	Benet et al.	514	9	
	6,057,359	May 02, 2000	Eugster	514	449	
	6,090,955	Jul 18, 2000	Reszka et al.	549	510	
	6,096,331	Aug 01, 2000	Desai et al.	424	422	
	6,136,846	Oct 24, 2000	Rubinfeld et al.	514	449	
	6,319,943	Nov 20, 2001	Joshi et al.	514	449	

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	CH 688 504	Oct 31, 1997	CH (Swedish)	A61K	031/015		X
	GB 2 257 359	Jan 13, 1993	GB	A61K	37/02		
	EP 0 211 079	Feb 25, 1987	EP	A61K	7/00		
	EP 0 919 228	Jun 02, 1999	EP	A61K	9/48		
	EP 1 029 539	Aug 23, 2000	EP	A61K	9/48		
	WO 96/05812	Feb 29, 1996	WIPO	A61K	9/52		
	WO 97/15329	May 01, 1997	WIPO (French)	A61K	47/12		X

Examiner

Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449  
(Rev. 8-88)U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

Serial No.

6239.N

10/047,902

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Ping Gao et al.

Filing Date

January 14, 2002

Group No.

1614

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 97/35527	Oct 02, 1997	WIPO	A61J	3/07		
	WO 98/53811	Dec 03, 1998	WIPO	A61K	31/335		
	WO 98/58927	Dec 30, 1998	WIPO	C07D	405/02		
	WO 99/45918	Sep 16, 1999	WIPO	A61K	31/335		
	WO 99/06024	Feb 11, 1999	WIPO	A61K	9/107		
	WO 00/18377	Apr 06, 2000	WIPO	A61K	9/48		
	WO 00/27367	May 18, 2000	WIPO	A61K	9/48		
	WO 00/28976	May 25, 2000	WIPO	A61K	9/48		
	WO 00/33862	Jun 15, 2000	WIPO	A61K	38/00		
	WO 00/72827	Dec 07, 2000	WIPO	A61K	9/16		
	WO 00/78247	Dec 28, 2000	WIPO	A61F	2/02		
	WO 01/03676	Jan 18, 2001	WIPO	A61K	9/48		
	WO 02/43765	Jun 06, 2002	WIPO	A61K	47/00		

## OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)

Ansel et al. (1995) *Pharmaceutical Dosage Forms and Drug Delivery Systems*, 6<sup>th</sup> Ed., pp 176-182.

Examiner

Date Considered

\*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP §609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

